Table 2:
Training cohort (n=207) | Validation cohort (n=316) | |||||||
---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
Age (< 65) | 0.71 (0.91 – 2.21) | 0.12 | 1.00 (0.66 – 1.53) | 0.99 | ||||
Male | 1.42 (0.85 – 2.49) | 0.18 | 1.10 (0.60 – 2.25) | 0.78 | ||||
Upper tumor | 2.04 (1.10 – 3.50) | 0.02 | 3.09 (1.64 – 5.45) | 0.001 | 0.95 (0.62 – 1.48) | 0.81 | ||
Preoperative therapy | 1.09 (0.71 – 1.66) | 0.7 | 1.96 (1.29 – 3.00) | 0.002 | 0.87 (0.49 – 1.53) | 0.61 | ||
TNM stage (III–IV) | 3.32 (2.05 – 5.63) | <0.0001 | 3.78 (2.30 – 6.46) | <0.0001 | 3.08 (2.03 – 4.72) | <0.0001 | 3.21 (1.81 – 5.70) | <0.0001 |
F. nucleatum High | 1.61 (1.06 – 2.52) | 0.03 | 1.72 (1.12 – 2.70) | 0.01 | 1.96 (1.23 – 3.04) | 0.004 | 1.70 (1.06 – 2.65) | 0.03 |